We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 529

Gilead Sciences Canada, Inc. v. Canada (Minister of Health), 2012 FC 2, Complera (tenofovir, emtricitabine and rilpivirine), patent listing decision

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 3 2012

In this case the Court accepted the Minister’s position that a patent with combination patent claims and formulation claims to a triple medicinal ingredient product was not eligible for listing

Supreme Court of Canada releases the Viagra decision

  • Osler Hoskin & Harcourt LLP
  • -
  • Canada
  • -
  • November 8 2012

In a unanimous decision released November 8, 2012, the Supreme Court of Canada has reversed the judgments of the Federal Court and the Federal Court of Appeal and cleared the way for an affordable generic version of Pfizer’s Viagra to be sold in Canada by Teva Canada Ltd

Court of Appeal upholds decision awarding Section 8 compensation where sales related to “unauthorized indications” Sanofi-Aventis Canada Inc. v. Teva Canada limited, 2014 FCA 69

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 24 2014

Drug: ramipril This was an appeal by Sanofi-Aventis Canada Inc. and Sanofi-Aventis Deutschland GmbH (collectively "Sanofi") from a judgment of the

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in

Federal Court grants one of three prohibition applications for VIGAMOX eye drops containing moxifloxacin hydrochloride

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 1 2014

This latest decision from the Federal Court is consistent with a recent trend towards a more literal construction of patent claims. The Court

Amendments to the PM(NOC) Regulations proposed

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • December 3 2014

Industry Canada recently released its Forward Regulatory Plan 2014-2016, setting out the planned initiatives it expects to bring forward over the

Court of Appeal again interprets utility requirement in Celebrex FCA

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 1 2014

The Federal Court of Appeal has again discussed the so-called “promise doctrine” in its October 30, 2014 decision of Apotex Inc. v. Pfizer Canada Inc

Canada joins the gene patenting debate

  • Foley & Lardner LLP
  • -
  • Canada
  • -
  • November 23 2014

Canada has joined the gene patenting debate. Children’s Hospital of Eastern Ontario (“Children’s”) sued the University of Utah Research

Patent term restoration for Canadian pharmaceutical patents

  • Norton Rose Fulbright LLP
  • -
  • Canada, European Union
  • -
  • November 28 2014

The signature of the free-trade agreement texts between Canada and the European Union provided additional details on the provisions relating to the

Sanofi-Aventis, et al. V. Apotex Inc., et al.

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • November 10 2014

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis